Table 1

Oxo-M inhibition of agonist-stimulated cAMP accumulation

Agonist	Fold Stimulation^1-a		Total Inhibition^1-b	Inhibition of Agonist-Simulated^1-b
Agonist	Control	+1 μM Oxo-M	Total Inhibition^1-b	Inhibition of Agonist-Simulated^1-b
			%	%
Forskolin (10 μM)	14.93 ± 3.14	4.79 ± 1.04	67.1 ± 3.06	70
Isoproterenol (1 μM)	2.51 ± 0.25	1.59 ± 0.08	32.8 ± 4.57	38
PGE₁ (10 μM)	2.27 ± 0.15	1.66 ± 0.08	26.5 ± 2.37	20
PGE₂(10 μM)	2.28 ± 0.28	1.56 ± 0.07	29.4 ± 6.85	29
Dopamine (10 μM)	1.42 ± 0.20	0.96 ± 0.07	29.9 ± 5.24	26
Cicaprost (0.8 μM)	2.45 ± 0.25	2.03 ± 0.23	17.0 ± 3.08	5
PGI₂(10 μM)	1.52 ± 0.12	1.35 ± 0.21	12.4 ± 7.12	0^1-c
5-HT (10 μM)	1.43 ± 0.20	0.98 ± 0.09	25.0 ± 3.06	23
5-MT (10 μM)	1.25 ± 0.05	0.92 ± 0.11	26.5 ± 7.99	0^1-c
Dimaprit (10 μM)	1.32 ± 0.12	1.04 ± 0.17	21.7 ± 6.92	0^1-c
VIP (10 μM)	1.33 ± 0.16	0.85 ± 0.06	33.0 ± 9.06	39
SKF-38393 (10 μM)	1.08 ± 0.05	0.86 ± 0.03
2-Chloroadenosine (10 μM)	1.09 ± 0.07	0.92 ± 0.03
CGS-21680 (10 μM)	1.12 ± 0.03	0.81 ± 0.05
PGD₂ ^1-d (10 μM)	1.08 ± 0.06	1.00 ± 0.07
Secretin (10 μM)	0.93 ± 0.03	0.93 ± 0.01
Vasopressin (10 μM)	0.97 ± 0	0.97 ± 0.01

↵1-a Fold stimulation over basal, mean ± S.E.M. of 3 to 12 experiments.
↵1-b Inhibition expressed only for agents that elicited significant stimulation.
↵1-c Negative percent effect.
↵1-d PGD₂, prostaglandin D₂.